Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, reported financial results …
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, announced that …
Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, today reported …
Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, announced the …
Catalyst Pharmaceutical (NASDAQ: CPRX) is a company who develops therapeutic solutions for rare diseases. The company recently closed a previously announced public offering on …
In a research report published Monday, Roth Capital analyst Scott Henry reiterated a Buy rating on Catalyst Pharmaceutical (NASDAQ:CPRX) with a $6.00 price …
Roth Capital analyst Scott Henry maintained a Buy rating on Catalyst Pharmaceutical (NASDAQ:CPRX) with a $6.00 price target, following the company’s third-quarter results, …
In a research report released today, H.C.
Catalyst Pharmaceutical (NASDAQ:CPRX) announced after the close Monday positive top-line results from the pivotal phase 3 clinical trial of Firdapse to treat Lambert-Eaton …
In a research note released today to investors, H.C.
